Gastric Stimulation in the Digestive Period Modifies Length and Contractility of the Inter-digestive Period in Obese Non-diabetic and Diabetic Subjects

Bohdjalian, A.; Aviv, R.; Prager, G.; Schindler, K.; Bacher, E.; Langer, F.; Ludvik, B.
September 2012
Obesity Surgery;Sep2012, Vol. 22 Issue 9, p1465
Academic Journal
Background: The association between phase II of the motor migratory complex (MMC) and hunger remains poorly understood, which may be important in non-diabetic and diabetic obese subjects where gastric inter-digestive motility has been often reported as impaired. We characterize phase II of the MMC and its predictive power on food intake, weight loss, and glycemia in non-diabetic (OB) and diabetic (DM) obese subjects treated with gastric stimulation for 6 months. Methods: Twelve OB and 12 DM subjects were implanted with bipolar electrodes connected to a gastric stimulator capable of recording antrum electromechanical activity. Results: The phase II mean interval size and duration increased from 156 ± 121 to 230 ± 228 s and from 98 ± 33 to 130 ± 35 min ( p < 0.05) in OB and from 158 ± 158 to180 ± 112 s and from 77 ± 26 to 109 ± 18 min ( p < 0.05) in DM after 6 months. There was a significant trend of meals to interrupt the late rather than the early phase II. Nonlinear regression analysis demonstrated that weight loss in OB was significantly associated with the change in interval size of the late phase II and with phase II duration. In the DM group, weight loss and glycemia were also significantly associated with the change in the interval size of the early phase II. Conclusions: Gastric stimulation delivered in the digestive period can modify the length of the MMC and the contractility in its longest component, phase II. The duration and contractility of the MMC can determine to some extent future intake and, thus, influence energy balance.


Related Articles

  • Treating Patients with "DIABESITY": Challenges and Opportunities. Still, Christopher // Bariatric Times;May2015, Vol. 12 Issue 5, p3 

    The author discusses the newer medications that treat type 2 diabetes mellitus (T2DM) while helping patients with weight loss and maintenance. He cites Metformin as an insulin sensitizer that works on the liver to help the body be more sensitive or use insulin more efficiently so the body does...

  • First six patients in EndoBarrier clinical trial reach 12-month mark. PEDERSEN, AMANDA // Medical Device Daily;3/4/2010, Vol. 14 Issue 42, p1 

    The article discusses initial results from a clinical trial evaluating 12 months of treatment with the EndoBarrier Gastrointestinal Liner developed by GI Dynamics. The technology is a non-surgical treatment for Type 2 diabetes and obesity. It was observed that the first six of 22 patients from...

  • GI Dynamics adds centers in Europe.  // Medical Device Daily;6/24/2013, Vol. 17 Issue 121, p7 

    The article reports on the distribution of the EndoBarrier weight-loss device for treating obesity and diabetes by GI Dynamics Inc. in five centers in Europe.

  • NUTRITION THERAPY IN THE TREATMENT OF OVERWEIGHT AND OBESE ADULTS WITH TYPE 2 DIABETES. Vasilescu, Razvan // Romanian Medical Journal;2015, Vol. 62 Issue 2, p162 

    It is well known the role of diet in the management of overweight and obese type 2 diabetic patients. Even a modest weight loss (5% to 10% of total body weight) is associated with improvements of cardiovascular risk factors. The traditional recommendations regarding the intake of macronutrients...

  • 'Mindful Eating' Lowers Weight, Blood Sugar in Diabetes.  // Today's Dietitian;Jan2013, Vol. 15 Issue 1, p60 

    The article reports that consuming food as per hunger requirements is as effective as following nutrition guidelines which helps in reducing weight and also controls the blood sugar level in patients with type 2 diabetes. It describes the two types of behavioral interventions including...

  • Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. Davies, Melanie J.; Bergenstal, Richard; Bode, Bruce; Kushner, Robert F.; Lewin, Andrew; Skjøth, Trine Vang; Andreasen, Arne Haahr; Jensen, Christine Bjørn; DeFronzo, Ralph A. // JAMA: Journal of the American Medical Association;8/18/2015, Vol. 314 Issue 7, p687 

    IMPORTANCE Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently available. OBJECTIVE To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and...

  • Managing diabetes in obese patients. Haslam, David // Independent Nurse;4/4/2011, p34 

    The author discusses the clinical importance of managing obesity in patients with diabetes. He refers to the Nurses Health Study in describing the close relationship between obesity and diabetes. He explains the four principles to be considered in estimating obesity management including...

  • Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints. Holmes, Amey; Coppey, Lawrence J.; Davidson, Eric P.; Yorek, Mark A. // Journal of Diabetes Research;7/2/2015, Vol. 2015, p1 

    We examined whether reversal of high fat diet, stimulating weight loss, compared to two treatments previously shown to have beneficial effects, could improve glucose utilization and peripheral neuropathy in animal models of obesity and type 2 diabetes. Rats were fed a high fat diet and treated...

  • Intensified treatment with insulin detemir improved glycemic control, weight loss.  // Endocrine Today;Oct2011, Vol. 9 Issue 10, p20 

    The article reports that a randomized trial has found that adding insulin detemir to a treatment regimen of metformin and liraglutide resulted to improved glycemic control and sustained weight loss for up to 52 weeks in patients with type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics